Eli Lilly and Company (LLY)

Check out top investors' recommendation for LLY
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
84.86
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
57%/43%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s neuroscience products treat major depressive disorders; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; bipolar depression and treatment-resistant depression; and brain imaging of beta-amyloid plaques. Its endocrinology products treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. The company’s oncology products treat malignant pleural mesothelioma; pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as cardiovascular products, which are used treat erectile dysfunction, benign prostatic hyperplasia, high cholesterol, pulmonary arterial hypertension; reduce thrombotic cardiovascular events; and used as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to improve milk productivity in dairy cows; anticoccidial agents; antibiotics to control enteric infections in calves and swine; products to treat canine separation anxiety; products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections; and other pharmaceutical products to treat staphylococcal and bacterial infections. The company distributes its products through independent wholesale distributors; and directly to pharmacies. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
John Boris Citi Buy   Sep 13, '17     96.00  Sep 13, '18  N/A 
Alex Arfaei BMO Capital Markets Sell   Sep 08, '17     71.00  Sep 08, '18  N/A 
Richard Purkiss Atlantic Equities Buy   Aug 31, '17     103.00  Aug 31, '18  N/A 
Ian Somaiya Piper Jaffray Sell   Aug 30, '17     73.00  Aug 30, '18  N/A 
Jeffrey Holford Jefferies & Co. Buy   Aug 24, '17     89.00  Aug 24, '18  N/A 
Vamil Divan Credit Suisse Buy   Jul 21, '17     89.00  Jul 21, '18  N/A 
Alex Arfaei BMO Capital Markets Sell   Jul 19, '17     73.00  Jul 19, '18  N/A 
Jeffrey Holford Jefferies & Co. Buy   Jun 22, '17       Jun 22, '18  N/A 
Alex Arfaei BMO Capital Markets Sell   Apr 17, '17       Apr 17, '18  N/A 
Steve Scala Cowen And Company Buy   Apr 17, '17     95.00  Apr 17, '18  N/A 
Seamus Fernandez Leerink Swann Llc Buy   Mar 20, '17       Mar 20, '18  N/A 
Geoff Meacham JPMorgan Buy   Jan 31, '17     85.00  Jan 31, '18  N/A 
Andrew Baum Citi Buy   Jan 19, '17     100.00  Jan 19, '18  N/A 
Jami Rubin Goldman Sachs Buy   Jan 18, '17     92.00  Jan 18, '18  N/A 
Jeffrey Holford Jefferies & Co. Buy   Jan 13, '17     90.00  Jan 13, '18  N/A 
Alex Arfaei BMO Capital Markets Buy   Nov 03, '16     91.00  Nov 03, '17  N/A 
Jeffrey Holford Jefferies & Co. Buy   Oct 28, '16     100.00  Oct 28, '17  N/A 
Alex Arfaei BMO Capital Markets Buy   Sep 27, '16     94.00  Sep 27, '17  N/A 
Jeffrey Holford Jefferies & Co. Buy   Sep 14, '16     105.00  Sep 14, '17  N/A 
Seamus Fernandez Leerink Swann Llc Buy   Aug 13, '16     105.00  Aug 13, '17  N/A 
< previous1234